Page 1252 - Basic _ Clinical Pharmacology ( PDFDrive )

1238 Index

Receptor (Cont.): loop diuretics for, 263 idiosyncratic, 38
history of, 2 from potassium-sparing diuretics, 267 quantitative variations in, 38
inert binding sites in, 7 Renal potassium wasting, from carbonic variation in, 37–39
intracellular, for lipid-soluble agents, 27, anhydrase inhibitors, 261 Responsive neurostimulator, 411
27f Renal tubule transport mechanisms, Resting potential
macromolecular nature of, 21 254–259 on action potentials, 232–233, 233f
nomenclature for, 4–5 in collecting tubule system, 255f, of sodium channels, 233f
orphan, 21 257–259, 258f Restless legs syndrome, 506–507
response distal to, changes in compo- in distal convoluted tubule, 255f, 257, Rest tremor, 504
nents of, 38–39 257f Resynchronization, cardiac, 223
signaling mechanisms and drug action in loop of Henle, 255f, 256–257, 257f Retapamulin, 1070
in, 26–35 nephron segments and functions in, 256t Reteplase, 619
spare, and receptor-effector coupling, in proximal tubule, 254–256, 255f Retigabine, 411, 421, 433t, 437t
22f, 22–23 renal autacoids in, 259 Retinoic acid derivatives, 1077
types of, 21 Renin Retrograde signaling, 372
Receptor–drug interactions, 5 control of release of, 301–302, 302f Retrograde transmission, 90
Receptor-effector coupling, spare receptors description of, 300–301 Retroviral agents, 870–884
and, 22f, 22–23 Renin-angiotensin-aldosterone system drug-drug interactions of two-drug
Receptor ligand, endogenous, 38 in blood pressure regulation, 174 combinations of, 877t
Receptor recycling, opioid, 559 sites of action of drugs interfering with, entry inhibitors, 882–883
Receptor regulation, 32, 33f 187, 188f fundamentals of, 870
Receptor reserve, 22, 22f Renin-angiotensin system integrase strand transfer inhibitors,
Receptor tyrosine kinases inhibitors of, 304–305 883–884
description of, 27–28, 28f angiotensin-converting enzyme nonnucleoside reverse transcriptase
signaling function of, 27 inhibitors, 304–305 inhibitors, 876–879
Receptor uncoupling, opioid, 559 angiotensin receptor blockers, nucleoside and nucleotide reverse
Recombinant factor VIIa (rFVIIa), 616, 304–305 transcriptase inhibitors,
622t, 623, 624t prorenin receptors, 305 870–876, 871t–872t
Recombinant human insulin-like growth renin inhibitors, 302f, 305 in pregnancy, 879t
factor-binding protein-3 suppression of, hypertension treated protease inhibitors, 879–882
(rhIGFBP-3), 672 with, 300, 320 Reye’s syndrome, 1128
Red blood cells, 53 Renin inhibitors Rh 0 (D) immune globulin, 991
Red thrombi, 609 heart failure treated with, 220 Rheumatoid arthritis
Reductase inhibitors, 632. See HMG-CoA hypertension treated with, 192t description of, 649
reductase inhibitors preparations available, 318t treatment of, 642–659. See also
Reductions, 61t on renin-angiotensin system, 302f, 305 Analgesics; specific drugs
Red yeast rice, 634 on vasoactive peptides, 316t case study, 642, 666
Reentry, 234 Renshaw cells, 378 disease-modifying antirheumatic
Refractory period, 232–233, 233f Repaglinide, 759, 768t drugs, 649–659, 664t
Regadenoson, 206b Repinotan, 286 nonsteroidal anti-inflammatory drugs,
Regulation, drug, 10–18. See also Research. See also specific topics 643–649, 645t
Development and regulation, basic, 14b Rhinitis medicamentosa, 1128
drug translational, 12 Rho kinases (ROCK), 207
Regulation, flexible, 35 Reserpine, 285 rhPTH 1–84, 775, 790t
Regulatory proteins, as drug receptors, 21 Huntington’s disease treated with, 508t Rhythm, normal cardiac, 228–233
Relaxin, ovarian, 732 hypertension treated with, 179t, 182, Ribavirin
Relay neurons, 373, 373f 191t hepatitis C treated with, 891
Relcovaptan, 308, 317t. See also Vasopres- Resistance, antibiotic, 793 influenza A and B treated with, 893
sin receptor antagonists Reslizumab, 357, 363t, 994 Lassa fever and viral hemorrhagic fevers
Release inhibitors, histamine in, 281 Respiratory depressants, sedative-hypnotics, treated with, 893
Remifentanil, 555t, 567, 572t. See also 389 pegylated interferon with, 80t, 85
Opioid agonists Respiratory depression, opioid-induced, respiratory syncytial virus treated with,
Remodeling, cardiac, 216 561 893
“REM rebound,” 388 Respiratory syncytial virus (RSV), 1181t Rickets
Renal baroreceptor, on renin release, 301 Response axis, 36, 36f hereditary vitamin D–resistant, 788
Renal failure Response elements, 27 nutritional, 788
from ADH antagonists, 269 Response fluctuations, from levodopa, 497 pseudovitamin D deficiency, 788
diuretics for, 270–271 Responsiveness, drug Rifabutin, 843t, 849